Repurposing of Bisphosphonates for the Prevention and Therapy of Nonsmall Cell Lung and Breast Cancer

Agnes Stachnik,Tony Yuen,Jameel Iqbal,Miriam Sgobba,Yogesh Gupta,Ping Lu,Graziana Colaianni,Yaoting Ji,Ling-Ling Zhu,Se-Min Kim,Jianhua Li,Peng Liu,Sudeh Izadmehr,Jaya Sangodkar,Thomas Scherer,Shiraz Mujtaba,Matthew Galsky,Jorge Gomez,Solomon Epstein,Christoph Buettner,Zhuan Bian,Alberta Zallone,Aneel K. Aggarwal,Shozeb Haider,Maria I. New,Li Sun,Goutham Narla,Mone Zaidi
DOI: https://doi.org/10.1073/pnas.1421422111
IF: 11.1
2014-01-01
Proceedings of the National Academy of Sciences
Abstract:SignificanceSmall molecules to target oncogenic signaling cascades in cancer have achieved success in molecularly defined patient subsets. The path to approval is often protracted and plagued with failures. Repositioning Food and Drug Administration-approved drugs with known side effects has become a major focus. Bisphosphonates are a commonly prescribed therapy for osteoporosis and skeletal metastases. The drugs have also been associated with reduced tumor burden in some patients, but the mechanism is unknown. Here we provide evidence that bisphosphonates inhibit the human EGFR (HER) receptor tyrosine kinase, including the commonly mutated forms that drive nonsmall cell lung cancer, as well as a resistance mutation. This new mechanism lays the basis for the future use of bisphosphonates for the prevention and therapy of HER family-driven cancers.
What problem does this paper attempt to address?